Hall P A, Lemoine N R, Murphy G, Dowling R H
ICRF Molecular Oncology Group, Hammersmith Hospital, London.
Gut. 1991 May;32(5):533-5. doi: 10.1136/gut.32.5.533.
A series of molecular changes are now known to be seen in human pancreatic neoplasia, including the very frequent mutational activation of Kirsten ras oncogene at codon 12, overexpression of the epidermal growth factor receptor, and abnormalities of c-erbB-2 expression. In order to determine whether similar changes can be seen in animal models of pancreatic cancer a molecular analysis of tumours induced in rats by pancreaticobiliary diversion was performed. The polymerase chain reaction was used to amplify portions of the rat Kirsten ras gene and sequence specific oligonucleotide hybridisation was used to define whether sequences were wild type or mutant. No evidence of mutation was found in the Kirsten ras gene at codons 12 or 61, where activating mutations are known to occur. In addition immunohistochemical methods were used to investigate expression of c-erB-2 and the epidermal growth factor receptor but no evidence of abnormal expression was found. We conclude that there are major molecular differences between human and experimental rat pancreatic cancer.
现已发现人类胰腺肿瘤会出现一系列分子变化,包括第12密码子处的 Kirsten ras 癌基因频繁发生突变激活、表皮生长因子受体过度表达以及 c-erbB-2 表达异常。为了确定在胰腺癌动物模型中是否能观察到类似变化,对胰胆管转流诱导的大鼠肿瘤进行了分子分析。采用聚合酶链反应扩增大鼠 Kirsten ras 基因的部分片段,并使用序列特异性寡核苷酸杂交来确定序列是野生型还是突变型。在已知会发生激活突变的第12或61密码子处,未在 Kirsten ras 基因中发现突变证据。此外,采用免疫组织化学方法研究 c-erB-2 和表皮生长因子受体的表达,但未发现异常表达的证据。我们得出结论,人类胰腺癌与实验性大鼠胰腺癌之间存在主要分子差异。